Status:
COMPLETED
Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborating Sponsors:
Gustave Roussy, Cancer Campus, Grand Paris
Conditions:
Thyroid Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
One of the most effective treatments for metastases from thyroid cancer is a form of radioactive iodine known as 131-I. For more than 50 years, 131-I has been used to find and destroy thyroid cancer c...
Eligibility Criteria
Inclusion
- Adult thyroid carcinoma patients who have had a total thyroidectomy, histology confirmed by an MSKCC attending pathologist, and radioiodine remnant ablation.
- Adult thyroid carcinoma patients who have previously demonstrated radioiodine-avid metastases and are about to undergo Thyrogen-assisted dosimetry at MSKCC.
- The patient and physician are planning to administer 131-I for therapy if persistent radioiodine-avid metastases are present.
- Men and women of all races, ethnicities, and religious backgrounds are eligible.
- All subjects must have measurable disease, documented within the previous six months by ultrasonography (US), MRI, or non-contrast CT scanning.
Exclusion
- Thyroid cancer patients who do not have metastases.
- Thyroid cancer patients who have not demonstrated that their metastases concentrate radioiodine.
- Patients who are under therapy for other active cancers.
- Anaplastic or Medullary thyroid carcinoma.
- Age less than 18 years.
- Patient who have received a therapeutic dose of radioiodine within the preceding nine months will not be eligible.
- Patients who plan to withdraw from thyroid hormone prior to dosimetry.
- Patients who are pregnant.
Key Trial Info
Start Date :
March 7 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 2 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00673010
Start Date
March 7 2005
End Date
October 2 2025
Last Update
October 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065